A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer

A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer

Abstract There are few effective treatments for small cell lung cancer (SCLC) underscoring the need for innovative therapeutic approaches. This study focuses on exploiting telomerase, a critical SCLC dependency as a therapeutic target. A prominent characteristic of SCLC is their reliance on telomera...

Full description

Bibliographic Details
Main Authors: Buse Eglenen-Polat, Ryan R. Kowash, Hai-Cheng Huang, Silvia Siteni, Mingrui Zhu, Kenian Chen, Matthew E. Bender, Ilgen Mender, Victor Stastny, Benjamin J. Drapkin, Prithvi Raj, John D. Minna, Lin Xu, Jerry W. Shay, Esra A. Akbay
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-44861-8

Internet

https://doi.org/10.1038/s41467-024-44861-8

Similar Items